GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Issuance of Debt

Oncopeptides AB (LTS:0RN4) Issuance of Debt : kr0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Issuance of Debt?

Oncopeptides AB's Issuance of Debt for the three months ended in Sep. 2024 was kr0.00 Mil.

Oncopeptides AB's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00 Mil.

Oncopeptides AB Issuance of Debt Historical Data

The historical data trend for Oncopeptides AB's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Issuance of Debt Chart

Oncopeptides AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 116.02

Oncopeptides AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Oncopeptides AB Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Issuance of Debt
Comparable Companies
OSTO:ACE XSAT:CURAS OSTO:ALZ OSTO:KDEV OSTO:ISOFOL XSAT:CESSA OSTO:LIPUM OSTO:CANTA OSTO:XINT OSTO:CLBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ONCO:Sweden OND:Germany
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Website
https://www.oncopeptides.com
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines